ImageBiopsy Lab participating in Philips HealthWorks Program

The ImageBiopsy Lab team is thrilled to participate in this innovative program. With the help of industry experts such as Philips, we believe that AI has the potential to revolutionize healthcare. Stay tuned for more news during this exciting journey!

We are thrilled to announce that ImageBiopsy Lab was selected to participate in the Philips HealthWorks acceleration program in Eindhoven. As a startup applying Deep Learning to bone diseases, we are perfect match for the “AI in Healthcare” Global Startup Program 2018. For 12 weeks, our team will be working together with industry leaders and experts of the health tech industry.

The Philips HealthWorks program is a world-first acceleration program focusing on early stage startups. This cycle’s focus lies on applying AI to Radiology, Ultrasound and Oncology. The program runs across multiple locations in the U.S., Europe, India and China. This “AI in Healthcare” program will enable the participants to work with Philips’ ecosystem. This consists of hospitals and clinicians, as well as investors, partners and coaches.

The overall goal of Philips HealthWorks and this program in particular is to tackle the challenges of applying AI in healthcare. Together with leading startups in the field, they aim to increase speed, comfort and confidence in this new disruptive technology.

Build, test, grow, scale

The program is tailored to the needs and ideas of each startup. A core program covering topics such as IP Generation or Quality and Regulatory are available for all startups. However, there is no “one size fits all” schedule. An Immersion Period of two weeks will help set individual goals, as well as familiarize the Philips HealthWorks team with the startups. Following this period, an intense Experiment and Learn Phase of 9 weeks will lead the participants through numerous iterations of establishing value propositions and strong business cases. Finally, a Pitch Week will culminate in a final Breakthrough Day presentation.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)